Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Cellectar Biosciences, Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03478462CT.gov Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pediatric Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Iopofosine (¹³¹I) (this asset) | Cellectar Biosciences, Inc. | P1 | CC · 43 |
| Genistein | University of Virginia | P2 | CCC |
| Cyclophosphamide | Actuate Therapeutics Inc. | P1 | CC |
| Nogitecan | Actuate Therapeutics Inc. | P1 | CC |
| Elraglusib | Actuate Therapeutics Inc. | P1 | CC |
| Irinotecan | Actuate Therapeutics Inc. | P1 | CC |
| Decitabine | Children's Hospital Medical Center, Cincinnati | Early P1 | CC |
| Pembrolizumab | Children's Hospital Medical Center, Cincinnati | Early P1 | CC |
Other indications for Iopofosine (¹³¹I)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Waldenstrom Macroglobulinemia | — | P2 | CCC · 53 |
| Lymphoplasmacytic Lymphoma | — | P2 | CCC · 53 |
| Primary Central Nervous System Lymphoma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Iopofosine (¹³¹I) in Pediatric Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/iopofosine-i-pediatric-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →